CONTEXT: Dysregulated cell proliferation caused by inhibitors of programmed cell death (apoptosis) contributes to tumor progression and spread. Aberrant expression of Bcl-2, the most notable inhibitor of apoptosis, has been well characterized in several human malignancies. Recent studies have described a novel apoptosis inhibitor, survivin, in human carcinomas, although its exact role remains to be characterized. OBJECTIVE: The purpose of this study was to evaluate the immunohistochemical expression of Bcl-2 and survivin proteins in prostate cancer and to correlate the results with clinicopathologic variables. DESIGN: Formalin-fixed, paraffin-embedded tissue sections from 138 cases of prostatic adenocarcinomas (PACs) were immunostained by an automated method using specific antibodies against survivin and Bcl-2. Staining was semiquantitatively scored based on both intensity and distribution, and results were correlated with morphologic and prognostic variables. RESULTS: Of the 138 PACs tested, 113 (82%) expressed survivin. We found no correlation between survivin expression and prognostic variables, including grade, stage, DNA content (ploidy), and recurrence. Bcl-2 expression was positive in 95 (69%) of these 138 cases and correlated with nondiploid DNA content. Fourteen (50%) of 28 nondiploid PACs expressed Bcl-2, compared to 17 (25%) of 68 diploid tumors (P =.02). A trend for association of Bcl-2 expression with tumor stage was noted as follows: 21 (39%) of 54 advanced-stage PACs expressed Bcl-2, in comparison with 20 (24%) of 84 low-stage tumors (P =.07). On univariate analysis, 25 (48%) of the 52 PACs that recurred expressed Bcl-2, as compared with 16 (19%) of the 86 nonrecurrent PACs (P <.001). No correlation was noted between survivin and Bcl-2 expression. CONCLUSION: Survivin is expressed in a majority of PACs and is not a prognosis-related marker, but may be a potential target for apoptosis-based therapy. Overexpression of Bcl-2 correlates with other prognostic variables and predicts disease recurrence of PACs. These data also suggest that survivin and Bcl-2 may regulate cell proliferation and cell death through different mechanisms.
CONTEXT: Dysregulated cell proliferation caused by inhibitors of programmed cell death (apoptosis) contributes to tumor progression and spread. Aberrant expression of Bcl-2, the most notable inhibitor of apoptosis, has been well characterized in several humanmalignancies. Recent studies have described a novel apoptosis inhibitor, survivin, in humancarcinomas, although its exact role remains to be characterized. OBJECTIVE: The purpose of this study was to evaluate the immunohistochemical expression of Bcl-2 and survivin proteins in prostate cancer and to correlate the results with clinicopathologic variables. DESIGN:Formalin-fixed, paraffin-embedded tissue sections from 138 cases of prostatic adenocarcinomas (PACs) were immunostained by an automated method using specific antibodies against survivin and Bcl-2. Staining was semiquantitatively scored based on both intensity and distribution, and results were correlated with morphologic and prognostic variables. RESULTS: Of the 138 PACs tested, 113 (82%) expressed survivin. We found no correlation between survivin expression and prognostic variables, including grade, stage, DNA content (ploidy), and recurrence. Bcl-2 expression was positive in 95 (69%) of these 138 cases and correlated with nondiploid DNA content. Fourteen (50%) of 28 nondiploid PACs expressed Bcl-2, compared to 17 (25%) of 68 diploid tumors (P =.02). A trend for association of Bcl-2 expression with tumor stage was noted as follows: 21 (39%) of 54 advanced-stage PACs expressed Bcl-2, in comparison with 20 (24%) of 84 low-stage tumors (P =.07). On univariate analysis, 25 (48%) of the 52 PACs that recurred expressed Bcl-2, as compared with 16 (19%) of the 86 nonrecurrent PACs (P <.001). No correlation was noted between survivin and Bcl-2 expression. CONCLUSION: Survivin is expressed in a majority of PACs and is not a prognosis-related marker, but may be a potential target for apoptosis-based therapy. Overexpression of Bcl-2 correlates with other prognostic variables and predicts disease recurrence of PACs. These data also suggest that survivin and Bcl-2 may regulate cell proliferation and cell death through different mechanisms.
Authors: Min Zhang; Alex Ho; Elizabeth H Hammond; Yoshiyuki Suzuki; R Scott Bermudez; R Jeffrey Lee; Michael Pilepich; William U Shipley; Howard Sandler; Li-Yan Khor; Alan Pollack; Arnab Chakravarti Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-30 Impact factor: 7.038
Authors: Daniel Westaby; Juan M Jimenez-Vacas; Ana Padilha; Andreas Varkaris; Steven P Balk; Johann S de Bono; Adam Sharp Journal: Cancers (Basel) Date: 2021-12-23 Impact factor: 6.639
Authors: Usha Malhotra; Ali H Zaidi; Juliann E Kosovec; Pashtoon M Kasi; Yoshihiro Komatsu; Christina L Rotoloni; Jon M Davison; Clint R; Toshitaka Hoppo; Katie S Nason; Lori A Kelly; Michael K Gibson; Blair A Jobe Journal: PLoS One Date: 2013-11-04 Impact factor: 3.240
Authors: Franziska Büscheck; Mariam Sulimankhil; Nathaniel Melling; Doris Höflmayer; Claudia Hube-Magg; Ronald Simon; Cosima Göbel; Andrea Hinsch; Sören Weidemann; Jacob R Izbicki; Frank Jacobsen; Tim Mandelkow; Niclas C Blessin; Christina Möller-Koop; Florian Lutz; Florian Viehweger; Katharina Möller; Guido Sauter; Maximillian Lennartz; Eike Burandt; Patrick Lebok; Sarah Minner; Sarah Bonk; Hartwig Huland; Markus Graefen; Thorsten Schlomm; Christoph Fraune Journal: Cancer Med Date: 2020-01-01 Impact factor: 4.452